San Francisco-based Rad AI, which develops generative AI (GenAI) tools to improve radiology workflows, has raised $60 million in an oversubscribed Series C funding round that takes the total raised to date by the company to $140 million and comes just a few months after it closed a $50 million second round.

NPR's Steve Inskeep speaks with LinkedIn cofounder Reid Hoffman about his latest book, "Superagency: What Could Possibly Go Right With Our AI Future?"

We’re producing vastly more information than any of us can possibly consume—artificial intelligence may be the key to effectively making use of that data.

Techno-optimist, investor and LinkedIn co-founder Reid Hoffman has written a new book, “Superagency,” outlining his vision of an AI-powered future. On Wednesday, Feb. 5  T, Hoffman joins The Post’s Bina Venkataraman to discuss how AI could help address the world’s most urgent problems and the future of human agency in the AI era.

In an interview with LinkedIn News' Jessi Hempel, the tech visionary will explain why he believes AI has the potential to reshape humanity for the better.

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for solid tumors, including sarcoma, non-small cell lung cancer, mesothelioma, and head and neck squamous cell carcinoma.

The LinkedIn founder talks about his new book, ‘Superagency,’ and argues that people can use AI to reshape their daily work lives.

Plus: Caroline Kennedy calls Robert F. Kennedy Jr. a predator ahead of his confirmation hearing | State Dept. allows HIV meds distribution to proceed

Reid Hoffman, Greylock partner, Inflection AI and LinkedIn co-founder, and ‘Superagency' author, joins 'Squawk Box' to discuss China's DeepSeek AI development, impact on the AI technology race, AI investment outlook,

Dedicated to spotlighting global leaders, the Tarnopol series serves as a platform for addressing critical societal issues, including AI’s potential and ethical implications.

LinkedIn founder Reid Hoffman and Siddhartha Mukherjee, cancer researcher and author of the book “The Emperor of All Maladies,” have co-founded an

Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.